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Cancer registries provide information for cancer prevention, diagnosis and treatment. However, collecting detailed data
required by each of the registries causes problems for the front line clinicians who have to record the information. Defining a
single consistent dataset including all required data would reduce the effort involved in data collection. The aim of this study
was to compare datasets in multiple cancer registries and to clarify the differences between them, to explore the possibility
of defining a single consistent clinical dataset for cancer. Prostate cancer was selected as an exemplar target. All data
elements from five cancer registries in UK were categorized in six groups: demographics, referral, imaging, diagnosis,
treatment, and miscellaneous. The definitions of data elements were checked in detail by the first author. A domain expert
judged the relationship between similar elements and explained the reason for the judgements when it was not clear.As a
result, a set of unique data elements was created by eliminating overlaps in data elements. In addition, similar but distinct
data elements were grouped together. The total number of data elements (451) was reduced by 22% from the simple sum
(581) of the entries in each registry. There are large differences in treatment and miscellaneous, which reflects the interests
of each registry. Although the ratios vary by groups, from 40% (25/62) for demographics to 83% (33/40) for referral, it is
anticipated that the single consistent clinical dataset will improve the efficiency of data gathering.
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1. Backgrounds
As cancer is one of the major as well as severe
diseases worldwide, collecting clinical data for
cancer is critical both for research and for each
patient’s treatment.
There are many independent cancer registries, each
of which has a detailed specification, reflecting the
priorities of different agencies. Differences lie in
various parts, for example, in target, e.g. type of
cancer, viewpoint, i.e. whole process or focused
only to some part such as chemotherapy and
pathology, granularity of data, and so on.
Therefore, hospitals currently collect data for each
registry separately, which causes problems for the
front line clinicians who have to record the
information required by each of the registries.
Therefore, if difference between registries’
datasets are made clarified and data elements are
reduced by eliminating overlaps, it would reduce
cost of data collection. Moreover, defining a single
consistent dataset including all required data would
be beneficial in viewpoint of data quality.
2. Aim
The aim of this study was to compare datasets in
multiple cancer registries and to clarify the
differences between them in order to explore the
possibility of defining a consistent clinical dataset
for cancer.
3. Methods
Prostate cancer was selected as an exemplar target
for this research, because prostate cancer is the
most common solid cancer in men in UK and US.
We chose five registries below as sources of data
elements, because they are all the registries that
University College London Hospital have to submit
data to, for prostate cancer patients.
a) Cancer Outcomes and Services Dataset (COSD)
1)
b) Systemic Anti-Cancer Therapy Dataset (SACT)
2)
c) National Radiotherapy Dataset (RTDS) 3)
d) 100,000 Genomes Project (Genomics) 4)
e) National Prostate Cancer Audit (NPCA) 5)
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Firstly, all data elements belonging to the five
registries were listed up. Genomics dataset
includes data elements about genome sample
element, but we used only part of datasets from
Genomics, e.g., core clinical data. We excluded
include essential sample metadata because it was
information about the sample and participant, and
more focused on sample.
Next, all the data elements are categorized in six
groups, that is, diagnosis, imaging, demographics,
treatment, referrals and miscellaneous (misc),
firstly by the sections in each registry and secondly
by the name of the data elements, for example,
such as ‘patient characteristic’ in NPCA for
demographics and ‘Care episode – clinical
diagnosis (ICD)’ in RTDS for diagnosis.
Table 1 shows the numbers of data elements
belonging to each group.
　
Table 1 numbers of data elements belonging
to each group
Then, the definitions of data elements described in
the specifications were checked in detail. Domain
experts judged the relationship between similar
elements across registries. Data elements which
they judged equivalent were cross referenced to
each other. During the process, staffs without
domain knowledge supported experts’ task and
asked about the reason of the judgement.
As for some data elements, domain experts judged
that they are not exactly the same, but quite
similar. We put those data elements together as a
group.
4. Results
4.1 Data elements and groups
Table 2 is a part of our results as an example from
the diagnosis category.
Here the data element ‘primary diagnosis’ is
included in COSD, Genomics, SACT, and RTDS
but not in NPCA. SACT requires the primary
diagnosis at start systemic anti-cancer therapy, but
COSD document said ‘The primary diagnosis is
normally agreed at the MDT Meeting where the
patient is discussed.’ so we treated SACT 10
element as different from others but put all of them
in one group.
The data element ‘tumour laterality’ is only in
COSD.
Table 2 Sample data elements
4.2 Number of data elements
Table 3 shows the numbers of source elements,
data elements after eliminating overlaps and groups
belonging to each group.
　
Table 3 number of data elements after
eliminating overlaps
As shown in Table 3, the number of all the data
elements extracted from five registries were 581,
438 when excluding misc. After eliminating
overlapping elements, the total number of the data
elements became 451 (78% of simple sum of
source elements), 315 (72%) without misc. Here,
we counted data elements with different timing
separately, because each of them will require input
as one data element.
Table 4 describes the number of data elements
grouped by how many sources each of them has.
For example, Primary diagnosis (ICD) in Table2
has three sources, and Tumour Laterality has only
one source.
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Table 4 unique data elements and number
of overlaps
As for groups, the total numbers of the groups by
category are also shown in Table3.
4.3 Coverage in clinical studies
We compared data elements used in the recent
prostate cancer clinical studies and the data
elements in our dataset in order to evaluate the
coverage of our dataset in practical clinical
studies.
First, we collected 4 journal articles, for clinical
studies as type, including ‘prostate cancer’ in title
or in abstract from Pubmed. We excluded studies
for patients before diagnosis, then chose top 4
articles when sorted by publication date 6-9 ,11).
Next, we listed up all the data elements in patient
recruitment section, because data elements used in
intervention and evaluation are very specific to
each research protocol. On the other hand, data
elements used for patient screening are considered
more common and it will be beneficial if they are
standardized when extracting data from EMRs or
EHRs.
Then, we checked if they were included in our
dataset. Most data elements in the articles has
complicated structure such as ‘metastatic prostate
cancer‘. In such cases, we divided it into basic
elements such as ‘metastasis’, ‘prostate cancer’.
As a result, there were 43 parameters in patient
recruitment section in the four articles and they
were divided into 73 basic parameters. Among
them, 42 (58%) were included in our dataset and 31
(42%) were not. As for 43 original parameters in
the articles, 16 (37%) are assumed to be covered
using data elements in our dataset and 27 (63%)
aren’t.
5. Discussion
5.1 Related work
A lot of research has been done related to clinical
dataset. The authors found more than one thousand
articles with ‘clinical’, ’dataset’ and ‘cancer’ in
titles/abstract in PubMed, and 163 reviews for
these 10 years among them. Most of them were
about clinical studies using dataset, not focusing
on dataset itself.
Several projects have been trying to standardize
clinical dataset using clinical experts’
knowledge12-14). However, the authors could not
find any studies about comparison of data elements
in each dataset so far.
5.2 Evaluation of results
5.2.1 Number of data elements
As shown in Table 3, the number of data elements
was reduced about 20% by eliminating overlaps in
all categories. But the degree of reduction varies
according to the categories, that is, around 40% in
demographics whereas less than 20% in misc,
treatment and referral.
There are more treatment-specific data elements in
treatment and referral category. For example,
SACT requires detailed information about
chemotherapy in treatment category. RTDS needs
detailed appointment information in referral
category. It can be assumed that conduct
radiotherapy needs special facilities and referral to
them, while chemotherapy can be done within
clinic.
On the other hand, most registries require patient
identification and basic characteristics such as
gender and date of birth, which is considered the
reason of the highest percentage in demographics
category.
Zachary suggested to set a much smaller minimum
core data set for public research and additional
data elements for research 10). In fact, COSD has
such structures, core and other specific areas such
as urology and lung. In addition, Genomics and
NPCA provides linkage information between their
data elements and elements in COSD in their
specifications. However, we had to look into the
definition of each element carefully because some
of them look similar but are slightly different such
as data acquisition timing. More description would
be beneficial about the linkage and difference
between other registries in each registry’s
specification.
5.2.2 　Coverage in clinical studies
We found about one third of parameters used in
clinical studies were covered in our dataset.
Example of uncovered data elements are ‘life
expectancy’, ‘ongoing chemotherapy’, ‘cognitive
impairment’ and ‘treatment end date’.
We use registries as sources of data element, which
harnesses type of data, because cancer registries
doesn’t collect status, whole patient condition such
as concurrent disease which are required for
patient recruitment for clinical research. Registries
collect common data, and they don’t include
specific data required for prospective clinical
research.
During the evaluation, we faced several difficulties
in translating clinical phrases into simpler data
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elements, especially staffs without clinical
knowledge. Clinical doctors can judge easily those
information such as ‘disease progression’ from
patients’ overall condition or derive them from
consult letter. But covering this information using
simple dataset is not so easy.
In addition, we found that the some data element
required in patient recruitment are not covered in
our dataset, though very similar elements are
included. For example, values such as performance
status and PSA values at certain time points are
required, but data element in our dataset is time-
specific such as ‘PSA at diagnosis’. In order to
solve such problems, longitudinal data structure is
preferable and it will enhance our dataset use in
clinical practice and studies.
5.3 Limitation
We selected prostate cancer as target of analysis. It
is true that each type of cancer has its special
variables and options according to the
characteristic, such as TNM staging, specific
tumour marker, and specific investigation. In fact,
55 data elements (12%) in our dataset are prostate
cancer specific. We need more different data
elements for another type of cancer. However, the
method can be used to for analysis of other cancer
and the type of difference is not unique for prostate
cancer. Therefore this method is considered
generally available.
5.4 Future work
In this research, we tried to obtain a clinical
dataset for prostate cancer from multiple dataset of
cancer registries.
As the next step, we are planning to organize this
dataset into clinical concepts, which will be used
for an archetype-based information model to
support a range of applications, including one for
data entry. It is expected to enhance efficiency in
data input by using these integrated dataset.
6. Conclusion
The aim of this study was to compare datasets in
multiple cancer registries and to clarify the
differences between them in order to explore the
possibility of defining a consistent clinical dataset
for cancer. Data elements collected from five
registries about prostate cancer were checked in
detail and same and similar elements are put
together in groups. The total number of data
elements were reduced by about 20% after
eliminating overlaps. It is anticipated that the
single consistent clinical dataset will improve the
efficiency of data gathering
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